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Surprisingly, the role of contempo-
rary epidemiologic methods and gov-
ernmental institutions is not exam-
ined. No explanation is included of
how present-day public health offi-
cials go about detecting a problem,
how they define an epidemic, how
they use data such as incidence or
attack rates to identify the cause, and
how laws and regulations (e.g., vac-
cine requirements for school entry
and rules for production of food and
biological materials) are indispensa-
ble for disease prevention. The text
would have profited from another
round of editing to modify overly
forceful generalizations, tighten the
discussion, and check for historical
and medical accuracy. For example,
acyclovir is not AZT, and AZT was
not available for first-line treatment of
AIDS in the early 1980s; cholera is
not slowly creeping into the Western
Hemisphere, but it produced large
epidemics in Central and South
America in the 1990s; Figure 9.7B is
not an antivaccination statement from
Boston in 1902 but, as the engraving
itself indicates, a provaccine state-
ment from England in 1898; vaccina-
tion with Mycobacterium bovis BCG
does not cause the tuberculin test
result to be negative; and malaria con-
trol efforts in the United States were
not interrupted by World War II but,
on the contrary, were enhanced by the
creation of an agency called Malaria
Control in War Areas.
This is a concise and clear account
of the biologic and historical determi-
nants of epidemic diseases. It is
marred by a small number of factual
errors and a failure to include epi-
demiologic and public health methods
as components of the equation that
determines the power of plagues.
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This book offers advanced treat-
ment of a broad selection of topics in
molecular medical mycology
authored by leading investigators. It
assumes a foundation of knowledge
of mycotic pathogens and is suitable
for the reader who is well-grounded in
molecular microbiology. It is highly
recommended for investigators plan-
ning to conduct medical mycology
research. The book is divided into 5
sections: General Principles, Model
Systems, Specific Pathogens, The
Host, and Future Directions. Only
selected highlights are described here
because of space limitations. 
The book reviews the development
of transforming and gene-silencing
methods for identifying virulence
determinants. An overview of
Candida albicans virulence under-
lines that molecular subtyping has
elucidated 3 major clades, which dif-
fer in their potential for producing
superficial versus deep-seated infec-
tion. The first step in pathogenesis is
adherence to host tissues. The
endothelial and epithelial specificity
of members of the C. albicans Als
family of adherence molecules is
defined by the adherence profile of
null mutants. The discovery through
the genome sequence of C. albicans
mating type locus and the delineation
of the unique pathway of a parasexual
cycle are discussed. Although the
population is largely clonal and seems
locked in a diploid state, the species
has a demonstrated ability to undergo
recombination. 
The phylogenetic species concept
has led to a better understanding of
the lineage of pathogenic fungi, espe-
cially for the mitosporic fungi, which
have no known sexual stage. The evo-
lution of fungal species, shown by
multilocus sequence typing, enabled
construction of a phylogenetic tree of
all known fungal pathogens with
assignments to well-described fami-
lies and orders. 
Mechanisms of resistance to anti-
fungal agents are discussed, including
insights from genome sequence
analysis and recent clinical observa-
tions such as the role of transcription
factors in upregulating efflux pumps
in the presence of antifungal agents or
steroids. How environmental fungi
have acquired their pathogenic poten-
tial for humans, even those whose
immune function is intact, is a puzzle,
but clues come from the interaction of
fungi with soil-dwelling amebae.
Fungi escape endocytosis by convert-
ing from yeast to hyphal forms; this
not only conditions them for intracel-
lular survival but also suggests how
dimorphism may have originated.
Transcriptional profiling using
microarrays is a powerful tool for
identifying genes expressed during
mold-to-yeast morphogenesis and
host-fungus interactions in infected
tissue cultures and biofilms.
Interspersed in the book are examples
of exploiting this technology to dis-
cover key regulatory pathways. 
No subject attracts more interest,
yet is strewn with more pitfalls, thanBOOKS & MEDIA
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fungal vaccine development. Two
major types of vaccine development
are preventive vaccines and mono-
clonal antibody immunotherapy.
Individual recombinant antigens have
evoked mild to moderate protection.
Interest in a potential attenuated live
vaccine has been stimulated by the
finding that targeted disruption of the
Blastomyces dermatitidis gene, which
encodes the surface adhesin BAD-1,
renders the mutant avirulent. 
Of the chapters on specific
pathogens, the one covering virulence
mechanisms in Coccidioides immitis
is notable. It discusses application of
molecular approaches to identify key
proteins expressed during arthroconi-
dial and spherule morphogenesis at
each stage of the disease process and
to dissect the corresponding interac-
tions with the immune system.
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